abstract |
The present invention relates to the polypeptide, the use of the polypeptide in the prevention and/or treatment of side effects induced by plasminogen activators, specifically tPA or uPA. The invention further relates to combination compositions and/or therapy regimens, comprising the polypeptide and one or more currently used plasminogen activators, and methods to achieve improved fibrinolytic efficacy as well as reducing their side effects. |